Related Experiment Video
Updated: Jun 9, 2025
06:40
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
6.6K
Peptic Ulcer Disease: A Review.
1University of Wisconsin School of Medicine and Public Health, Madison.
JAMA
|October 28, 2024
Summary
Peptic ulcer disease, caused by H. pylori or NSAIDs, affects many. Treatment involves acid blockers and eradicating H. pylori, significantly reducing recurrence.
Area of Science:
- Gastroenterology
- Internal Medicine
- Epidemiology
Background:
- Peptic ulcer disease (PUD) affects 1% of the US population, with 54,000 annual hospitalizations for bleeding.
- Upper abdominal pain in primary care is often caused by PUD.
- Key causes include Helicobacter pylori (42%) and NSAID use (36%).
Purpose of the Study:
- To summarize the epidemiology, causes, complications, diagnosis, and treatment of peptic ulcer disease.
- To highlight the effectiveness of current treatments in healing ulcers and preventing recurrence.
Main Methods:
- Literature review and synthesis of epidemiological data on PUD prevalence, causes, and outcomes.
- Analysis of treatment efficacy for PUD, including acid suppression, H. pylori eradication, and NSAID management.
Main Results:
- PUD complications include bleeding (73%), perforation (9%), and obstruction (3%), with 10,000 annual deaths in the US.
- Proton pump inhibitors (e.g., omeprazole) heal 80-100% of ulcers within 4-8 weeks.
- H. pylori eradication reduces recurrence from 50-60% to 0-2%; discontinuing NSAIDs heals 95% of ulcers and reduces recurrence from 40% to 9%.
Conclusions:
- PUD is a significant cause of morbidity and mortality.
- Proton pump inhibitors are the primary treatment for healing ulcers.
- Preventing recurrence involves H. pylori eradication and judicious NSAID use or co-therapy.
More Related Videos
Related Concept Videos
01:30Peptic Ulcer Disease I: Introduction
139
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
139
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
01:28Peptic Ulcer Disease II: Pathophysiology
303
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
303
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
362
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
362
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
91
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
91